MA28029A1 - Double helice d'arn d'interference possedant des extremites franches et des modifications en 3' - Google Patents

Double helice d'arn d'interference possedant des extremites franches et des modifications en 3'

Info

Publication number: MA28029A1
Authority: MA; Morocco
Prior art keywords: aryl; alkyl; propeller; changes; double
Prior art date: 2003-08-28

Application number

MA28861A

Other languages

English (en)

French (fr)

Inventor

Jan Weiler

Jonathan Hall

Jean-Charles Bologna

Francois Jean-Charles Natt

Robert Haener

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-28

Filing date

2006-03-08

Publication date

2006-07-03

2006-03-08 Application filed by Novartis Ag filed Critical Novartis Ag

2006-07-03 Publication of MA28029A1 publication Critical patent/MA28029A1/fr

Links

125000002877 alkyl aryl group Chemical group 0.000 abstract 4
125000000217 alkyl group Chemical group 0.000 abstract 4
125000003710 aryl alkyl group Chemical group 0.000 abstract 4
125000003118 aryl group Chemical group 0.000 abstract 4
125000005842 heteroatom Chemical group 0.000 abstract 4
108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 2
102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 2
125000000524 functional group Chemical group 0.000 abstract 2
208000035657 Abasia Diseases 0.000 abstract 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 abstract 1
238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
230000009368 gene silencing by RNA Effects 0.000 abstract 1
-1 hydroxypropyl Chemical group 0.000 abstract 1
238000012986 modification Methods 0.000 abstract 1
230000004048 modification Effects 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
150000004713 phosphodiesters Chemical class 0.000 abstract 1
239000002342 ribonucleoside Substances 0.000 abstract 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/311—Phosphotriesters
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Apparatus For Disinfection Or Sterilisation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

MA28861A 2003-08-28 2006-03-08 Double helice d'arn d'interference possedant des extremites franches et des modifications en 3' MA28029A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US49851403P	2003-08-28	2003-08-28

Publications (1)

Publication Number	Publication Date
MA28029A1 true MA28029A1 (fr)	2006-07-03

Family

ID=34272687

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA28861A MA28029A1 (fr)	2003-08-28	2006-03-08	Double helice d'arn d'interference possedant des extremites franches et des modifications en 3'

Country Status (21)

Country	Link
US (2)	US20070203084A1 (pt)
EP (3)	EP1660657A1 (pt)
JP (2)	JP2007503803A (pt)
KR (3)	KR20110007263A (pt)
CN (2)	CN1845993B (pt)
AU (1)	AU2004269150C1 (pt)
BR (1)	BRPI0413146A (pt)
CA (1)	CA2536333C (pt)
CO (1)	CO5680494A2 (pt)
EC (1)	ECSP066388A (pt)
IL (1)	IL173565A (pt)
IS (1)	IS8358A (pt)
MA (1)	MA28029A1 (pt)
MX (1)	MXPA06002216A (pt)
NO (1)	NO20061345L (pt)
NZ (1)	NZ545360A (pt)
RU (2)	RU2399671C2 (pt)
SG (1)	SG152279A1 (pt)
TN (1)	TNSN06065A1 (pt)
WO (1)	WO2005021749A1 (pt)
ZA (1)	ZA200601003B (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1845993B (zh)	2003-08-28	2010-06-23	诺瓦提斯公司	具有平端和3＇修饰的干扰rna双链体
GB0608838D0 (en)	2006-05-04	2006-06-14	Novartis Ag	Organic compounds
CA2666657A1 (en) *	2006-10-18	2008-04-24	Nastech Pharmaceutical Company Inc.	Nicked or gapped nucleic acid molecules and uses thereof
JP4900943B2 (ja) *	2006-12-25	2012-03-21	独立行政法人産業技術総合研究所	ヌクレアーゼ耐性及びｒｎａ干渉効果に優れた修飾型二本鎖ｒｎａ
ES2428009T3 (es)	2007-07-05	2013-11-05	Novartis Ag	ARNds para tratar infecciones virales
EP2260102A1 (en)	2008-03-25	2010-12-15	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by down-regulating frizzled-4 and/or frizzled-1
US20110311521A1 (en)	2009-03-06	2011-12-22	Pico Caroni	Novel therapy for anxiety
EP2241323A1 (en)	2009-04-14	2010-10-20	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Tenascin-W and brain cancers
EP2292266A1 (en)	2009-08-27	2011-03-09	Novartis Forschungsstiftung, Zweigniederlassung	Treating cancer by modulating copine III
WO2011036118A1 (en)	2009-09-22	2011-03-31	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by modulating mex-3
WO2011045352A2 (en)	2009-10-15	2011-04-21	Novartis Forschungsstiftung	Spleen tyrosine kinase and brain cancers
KR101718534B1 (ko)	2009-12-09	2017-03-22	닛토덴코 가부시키가이샤	Ｈｓｐ４７ 발현의 조절
EP3000885B1 (en)	2009-12-18	2018-07-25	Arrowhead Pharmaceuticals, Inc.	Organic compositions to treat hsf1-related diseases
WO2011076807A2 (en)	2009-12-23	2011-06-30	Novartis Ag	Lipids, lipid compositions, and methods of using them
JP2013519869A (ja)	2010-02-10	2013-05-30	ノバルティスアーゲー	筋肉成長のための方法および化合物
WO2011107586A1 (en)	2010-03-05	2011-09-09	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research,	Smoc1, tenascin-c and brain cancers
WO2011131611A1 (en)	2010-04-19	2011-10-27	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Modulating xrn1
US10913767B2 (en) *	2010-04-22	2021-02-09	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
CA3098080A1 (en)	2010-04-23	2011-10-27	Arrowhead Research Corporation	Organic compositions to treat beta-enac-related diseases
WO2011154485A1 (en)	2010-06-10	2011-12-15	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by modulating mammalian sterile 20-like kinase 3
WO2012168259A1 (en)	2011-06-06	2012-12-13	Novartis Forschungsstiftung, Zweigniederlassung	Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
MX368573B (es) *	2011-07-18	2019-10-08	Devgen Nv	Regulacion hacia abajo de la expresion de genes en plagas de insectos.
CN103930547A (zh)	2011-09-02	2014-07-16	诺华股份有限公司	用于治疗hsf1相关疾病的有机组合物
US20140314787A1 (en)	2011-11-08	2014-10-23	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute	Treatment for neurodegenerative diseases
EP2776838A1 (en)	2011-11-08	2014-09-17	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Early diagnostic of neurodegenerative diseases
EP2780017A1 (en)	2011-11-15	2014-09-24	Novartis AG	Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway
WO2013102825A1 (en)	2012-01-02	2013-07-11	Novartis Ag	Cdcp1 and breast cancer
CA2860676A1 (en)	2012-01-09	2013-07-18	Novartis Ag	Organic compositions to treat beta-catenin-related diseases
WO2013144240A1 (en)	2012-03-29	2013-10-03	Friedrich Miescher Institute For Biomedical Research	Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
EP3272868A1 (en)	2012-05-02	2018-01-24	Arrowhead Pharmaceuticals, Inc.	Organic compositions to treat kras-related diseases
CN108148838A (zh) *	2012-05-22	2018-06-12	奥利克斯医药有限公司	具有细胞内穿透能力的诱导rna干扰的核酸分子及用途
WO2014001482A1 (en)	2012-06-29	2014-01-03	Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research	Treating diseases by modulating a specific isoform of mkl1
WO2014006114A1 (en)	2012-07-05	2014-01-09	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	New treatment for neurodegenerative diseases
EP2869818A1 (en)	2012-07-06	2015-05-13	Novartis AG	Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
SG10201706960TA (en)	2013-02-28	2017-10-30	Arrowhead Res Corp	Organic compositions to treat epas1-related diseases
KR102144777B1 (ko) *	2013-06-19	2020-08-18	제이더블유중외제약 주식회사	결정형 메로페넴 삼수화물의 제조방법
EP3030902B1 (en)	2013-08-07	2019-09-25	Friedrich Miescher Institute for Biomedical Research	New screening method for the treatment friedreich's ataxia
EP3052107B1 (en)	2013-10-04	2018-05-02	Novartis AG	Organic compounds to treat hepatitis b virus
EP3052627B1 (en)	2013-10-04	2018-08-22	Novartis AG	Novel formats for organic compounds for use in rna interference
WO2015051044A2 (en)	2013-10-04	2015-04-09	Novartis Ag	Novel formats for organic compounds for use in rna interference
JP6694811B2 (ja)	2013-10-04	2020-05-20	ノバルティスアーゲー	ＲＮＡ干渉に使用するためのＲＮＡｉ剤用の３’末端キャップ
WO2015051135A2 (en)	2013-10-04	2015-04-09	Novartis Ag	Organic compositions to treat hepcidin-related diseases
KR101696704B1 (ko) *	2013-12-17	2017-01-16	주식회사 인코드젠	오프-타겟을 막기 위해 변형된 rna 간섭 유도 핵산 및 그 용도
WO2015189816A1 (en)	2014-06-13	2015-12-17	Friedrich Miescher Institute For Biomedical Research	New treatment against influenza virus
WO2016001830A1 (en)	2014-07-01	2016-01-07	Friedrich Miescher Institute For Biomedical Research	Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
EP3736334A1 (en)	2014-07-16	2020-11-11	Arrowhead Pharmaceuticals, Inc.	Rnai compositions to treat apoc3-related diseases
EP3169309B1 (en)	2014-07-16	2023-05-10	Novartis AG	Method of encapsulating a nucleic acid in a lipid nanoparticle host
EP3191592A1 (en)	2014-09-11	2017-07-19	Novartis AG	Inhibition of prmt5 to treat mtap-deficiency-related diseases
US20170298360A1 (en)	2014-09-24	2017-10-19	Friedrich Miescher Institute For Biomedical Research	Lats and breast cancer
EP3227446A1 (en)	2014-12-01	2017-10-11	Novartis AG	Compositions and methods for diagnosis and treatment of prostate cancer
EP3302525A2 (en)	2015-06-05	2018-04-11	Novartis AG	Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
WO2017072669A1 (en)	2015-10-28	2017-05-04	Friedrich Miescher Institute For Biomedical Research	Tenascin-w and biliary tract cancers
PH12018501207B1 (en)	2015-12-21	2024-02-23	Novartis Ag	Compositions and methods for decreasing tau expression
US9721645B1 (en)	2016-01-29	2017-08-01	Taiwan Semiconductor Manufacturing Company, Ltd.	SRAM arrays and methods of manufacturing same
WO2018047148A1 (en)	2016-09-12	2018-03-15	Novartis Ag	Compounds for the inhibition of mirna
US20180245065A1 (en)	2016-11-01	2018-08-30	Novartis Ag	Methods and compositions for enhancing gene editing
US11530413B2 (en)	2017-07-21	2022-12-20	Novartis Ag	Compositions and methods to treat cancer
US10597657B2 (en)	2017-09-11	2020-03-24	Arrowhead Pharmaceuticals, Inc.	RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
EP3788138A1 (en)	2018-05-02	2021-03-10	Novartis AG	Regulators of human pluripotent stem cells and uses thereof
SG11202105577TA (en)	2019-01-09	2021-06-29	Arrowhead Pharmaceuticals Inc	Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
AR131405A1 (es)	2022-12-20	2025-03-19	Novartis Ag	Ligasas modificadas y usos de las mismas
AR131406A1 (es)	2022-12-20	2025-03-19	Novartis Ag	Método de ligación de ácidos nucleicos
WO2025262452A1 (en)	2024-06-18	2025-12-26	Novartis Ag	Nucleic acid ligation method

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE269870T1 (de)	1989-10-24	2004-07-15	Isis Pharmaceuticals Inc	2'-modifizierte oligonukleotide
US6399754B1 (en)	1991-12-24	2002-06-04	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides
US6005087A (en)	1995-06-06	1999-12-21	Isis Pharmaceuticals, Inc.	2'-modified oligonucleotides
US5670633A (en)	1990-01-11	1997-09-23	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides that detect and modulate gene expression
FI115214B (fi)	1992-01-22	2005-03-31	Hoechst Ag	Menetelmä oligonukleotidianalogien valmistamiseksi ja niiden käyttö
US6033909A (en)	1992-01-22	2000-03-07	Hoechst Aktiengesellschaft	Oligonucleotide analogs, their preparation and use
ATE285477T1 (de)	1995-06-07	2005-01-15	Inex Pharmaceutical Corp	Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US5981501A (en)	1995-06-07	1999-11-09	Inex Pharmaceuticals Corp.	Methods for encapsulating plasmids in lipid bilayers
US5998203A (en) *	1996-04-16	1999-12-07	Ribozyme Pharmaceuticals, Inc.	Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
CA2289702C (en)	1997-05-14	2008-02-19	Inex Pharmaceuticals Corp.	High efficiency encapsulation of charged therapeutic agents in lipid vesicles
RU2217161C2 (ru) *	1997-08-26	2003-11-27	Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик (С.К.Р.А.С.)	Способ лечения вирусного гепатита
US6506559B1 (en)	1997-12-23	2003-01-14	Carnegie Institute Of Washington	Genetic inhibition by double-stranded RNA
US6211349B1 (en)	1998-12-30	2001-04-03	Oligos Etc., Inc.	Protonated/acidified nucleic acids and methods of use
EP2314700A1 (en)	1999-01-28	2011-04-27	Medical College of Georgia Research Institute, Inc	Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de)	1999-01-30	2000-08-17	Roland Kreutzer	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
GB9927444D0 (en)	1999-11-19	2000-01-19	Cancer Res Campaign Tech	Inhibiting gene expression
DE10160151A1 (de)	2001-01-09	2003-06-26	Ribopharma Ag	Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
US20050233329A1 (en)	2002-02-20	2005-10-20	Sirna Therapeutics, Inc.	Inhibition of gene expression using duplex forming oligonucleotides
US8202979B2 (en)	2002-02-20	2012-06-19	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2002081628A2 (en) *	2001-04-05	2002-10-17	Ribozyme Pharmaceuticals, Incorporated	Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
WO2003070918A2 (en) *	2002-02-20	2003-08-28	Ribozyme Pharmaceuticals, Incorporated	Rna interference by modified short interfering nucleic acid
WO2005019453A2 (en)	2001-05-18	2005-03-03	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
PT1309726E (pt)	2000-03-30	2010-03-08	Whitehead Biomedical Inst	Mediadores de interferência por rna específicos de sequência de rna
US20030190635A1 (en)	2002-02-20	2003-10-09	Mcswiggen James A.	RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
US20040259247A1 (en)	2000-12-01	2004-12-23	Thomas Tuschl	Rna interference mediating small rna molecules
EP1229134A3 (en)	2001-01-31	2004-01-28	Nucleonics, Inc	Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US20040019001A1 (en)	2002-02-20	2004-01-29	Mcswiggen James A.	RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US20030175950A1 (en)	2001-05-29	2003-09-18	Mcswiggen James A.	RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20070032441A1 (en)	2001-05-18	2007-02-08	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
CA2448320A1 (en) *	2001-05-29	2002-12-05	Sirna Therapeutics, Inc.	Ribozyme based treatment of female reproductive diseases
US20090247606A1 (en)	2001-08-28	2009-10-01	Sirna Therapeutics, Inc.	RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US8258288B2 (en)	2002-02-20	2012-09-04	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
AU2003207708A1 (en)	2002-02-20	2003-09-09	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of map kinase genes
ES2389024T3 (es) *	2002-08-05	2012-10-22	Silence Therapeutics Aktiengesellschaft	Moléculas de RNA interferentes de extremos romos
AU2003260370B2 (en) *	2002-08-05	2008-05-22	Silence Therapeutics Gmbh	Further novel forms of interfering RNA molecules
WO2004090105A2 (en) *	2003-04-02	2004-10-21	Dharmacon, Inc.	Modified polynucleotides for use in rna interference
US20070270360A1 (en) *	2003-04-15	2007-11-22	Sirna Therapeutics, Inc.	Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid
DK1620544T3 (en)	2003-04-17	2019-01-14	Alnylam Pharmaceuticals Inc	MODIFIED iRNA AGENTS
WO2005009346A2 (en)	2003-06-24	2005-02-03	Mirus Corporation	Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
CN1845993B (zh)	2003-08-28	2010-06-23	诺瓦提斯公司	具有平端和3＇修饰的干扰rna双链体
EP2399924B1 (en)	2004-05-27	2015-01-28	Alnylam Pharmaceuticals, Inc.	Nuclease resistant double-stranded ribonucleic acid
GB0608838D0 (en)	2006-05-04	2006-06-14	Novartis Ag	Organic compounds

2004
- 2004-08-27 CN CN2004800249803A patent/CN1845993B/zh not_active Expired - Lifetime
- 2004-08-27 EP EP04764573A patent/EP1660657A1/en not_active Ceased
- 2004-08-27 KR KR1020117000474A patent/KR20110007263A/ko not_active Ceased
- 2004-08-27 MX MXPA06002216A patent/MXPA06002216A/es active IP Right Grant
- 2004-08-27 CA CA2536333A patent/CA2536333C/en not_active Expired - Lifetime
- 2004-08-27 BR BRPI0413146-0A patent/BRPI0413146A/pt not_active IP Right Cessation
- 2004-08-27 RU RU2006109547/13A patent/RU2399671C2/ru not_active IP Right Cessation
- 2004-08-27 JP JP2006524342A patent/JP2007503803A/ja active Pending
- 2004-08-27 NZ NZ545360A patent/NZ545360A/en not_active IP Right Cessation
- 2004-08-27 US US10/569,927 patent/US20070203084A1/en not_active Abandoned
- 2004-08-27 KR KR1020087007645A patent/KR101059315B1/ko not_active Expired - Fee Related
- 2004-08-27 EP EP12151831A patent/EP2489737A1/en not_active Withdrawn
- 2004-08-27 WO PCT/EP2004/009599 patent/WO2005021749A1/en not_active Ceased
- 2004-08-27 CN CN2010101678324A patent/CN101914533B/zh not_active Expired - Fee Related
- 2004-08-27 EP EP10184568A patent/EP2338995A3/en not_active Withdrawn
- 2004-08-27 AU AU2004269150A patent/AU2004269150C1/en not_active Expired
- 2004-08-27 SG SG200902906-7A patent/SG152279A1/en unknown
- 2004-08-27 KR KR1020067004048A patent/KR20060087531A/ko not_active Ceased
2006
- 2006-02-03 ZA ZA200601003A patent/ZA200601003B/en unknown
- 2006-02-06 IL IL173565A patent/IL173565A/en active IP Right Grant
- 2006-02-22 EC EC2006006388A patent/ECSP066388A/es unknown
- 2006-02-27 TN TNP2006000065A patent/TNSN06065A1/en unknown
- 2006-03-08 MA MA28861A patent/MA28029A1/fr unknown
- 2006-03-17 IS IS8358A patent/IS8358A/is unknown
- 2006-03-21 CO CO06027688A patent/CO5680494A2/es not_active Application Discontinuation
- 2006-03-24 NO NO20061345A patent/NO20061345L/no not_active Application Discontinuation
2008
- 2008-12-18 US US12/338,601 patent/US8097716B2/en not_active Expired - Lifetime
2010
- 2010-05-14 RU RU2010119292/10A patent/RU2010119292A/ru not_active Application Discontinuation
- 2010-08-26 JP JP2010189117A patent/JP2011160796A/ja active Pending

Also Published As

Publication number	Publication date
ZA200601003B (en)	2007-04-25
CN1845993B (zh)	2010-06-23
NO20061345L (no)	2006-05-29
TNSN06065A1 (en)	2007-10-03
RU2006109547A (ru)	2007-10-10
US20090192113A1 (en)	2009-07-30
CO5680494A2 (es)	2006-09-29
KR20060087531A (ko)	2006-08-02
RU2010119292A (ru)	2011-12-10
KR101059315B1 (ko)	2011-08-24
CN1845993A (zh)	2006-10-11
AU2004269150C1 (en)	2010-11-18
KR20110007263A (ko)	2011-01-21
US20070203084A1 (en)	2007-08-30
IL173565A0 (en)	2006-07-05
EP1660657A1 (en)	2006-05-31
JP2007503803A (ja)	2007-03-01
US8097716B2 (en)	2012-01-17
IL173565A (en)	2012-07-31
EP2338995A2 (en)	2011-06-29
JP2011160796A (ja)	2011-08-25
RU2399671C2 (ru)	2010-09-20
EP2338995A3 (en)	2012-01-11
CN101914533A (zh)	2010-12-15
CN101914533B (zh)	2013-06-19
AU2004269150A1 (en)	2005-03-10
CA2536333A1 (en)	2005-03-10
SG152279A1 (en)	2009-05-29
ECSP066388A (es)	2006-08-30
AU2004269150B2 (en)	2009-06-04
WO2005021749A1 (en)	2005-03-10
CA2536333C (en)	2013-01-08
IS8358A (is)	2006-03-17
MXPA06002216A (es)	2006-04-27
KR20080034046A (ko)	2008-04-17
EP2489737A1 (en)	2012-08-22
NZ545360A (en)	2009-06-26
BRPI0413146A (pt)	2006-10-03

Publication	Publication Date	Title
MA28029A1 (fr)	2006-07-03	Double helice d'arn d'interference possedant des extremites franches et des modifications en 3'
EP1010691A3 (fr)	2002-06-19	Dérives de l'hydrazide, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
ATE239752T1 (de)	2003-05-15	Pyrimidinderivate als markierte bindungspartner
ATE277066T1 (de)	2004-10-15	Bicyclonucleosid-analoga
CA2192824A1 (en)	1995-12-21	Pyridone-carboxylic acid derivatives, processes for the preparation thereof and anti-tumor agents containing the pyridone-carboxylic acid derivatives
WO1999035157B1 (en)	1999-10-14	Novel erythromycin derivatives
BR9510207A (pt)	1997-11-04	Derivados de benzamidoxima processo para a sua preparação e fungicida para usa agricola e horticola
EP1285908A4 (en)	2005-09-21	SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES
KR910002873A (ko)	1991-02-26	티아졸로[5,4-b] 아제핀 화합물
CA2706872A1 (en)	2003-05-15	Intermediates for the preparation of lipoxin a4 analogs
FR2786188B1 (fr)	2002-10-31	Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
CA1106277A (en)	1981-08-04	Microbiocidal agents on the basis of alkyl- diguanidinium salts
ES2188481T3 (es)	2003-07-01	Derivados de polinalbufina.
DK0455300T3 (da)	1995-11-06	Barbitursyrederivater med insekticid virkning
PT1016409E (pt)	2004-09-30	Composicao liofilizada esfingoglicolipidos e o processo para a sua preparacao
KR900701779A (ko)	1990-12-04	옥시란유도체 및 그것을 유효성분으로 하는 제초제
KR870007901A (ko)	1987-09-22	N-치환된 사프라마이신 유도체 및 이의
CA2118052A1 (en)	1995-04-16	N-(Substituted Amino) Pyrrole Derivatives, Preparation Process Thereof, and Herbicidal Compositions
RU2008112549A (ru)	2009-10-20	Сочетание биологически доступного метионина с по меньшей мере одним эфирным маслом
BR9908960A (pt)	2000-12-05	Amino guanidinas cìclicas
EP1252878A3 (en)	2003-03-12	Hair-growing agent
KR970006283A (ko)	1997-02-19	신규 아민고리 화합물
KR900018005A (ko)	1990-12-20	사이클로프로파노일아미노산 아미드 유도체
KR970019858A (ko)	1997-05-28	이미노아세테이트를 포함하는 신규 티아졸 화합물, 그의 제조방법 및 유효성분으로서 그를 함유하는 살균제 조성물
DK1165584T3 (da)	2004-05-17	2'-substitueret RNA fremstilling